^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    ALK mutation

    i
    Other names: NBLST3, CD246, Anaplastic Lymphoma Kinase, Anaplastic Lymphoma Kinase (Ki-1), CD246 Antigen, Mutant Anaplastic Lymphoma Kinase, ALK, ALK Receptor Tyrosine Kinase, Anaplastic Lymphoma Receptor Tyrosine Kinase, ALK Tyrosine Kinase Receptor
    Entrez ID:
    238
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    2d
    An open-label, dose-escalation and dose-expansion clinical study to evaluate the safety, tolerability, pharmacokinetics and efficacy of combination therapy with LAT010 plus pembrolizumab in patients with locally advanced or metastatic solid tumors (ChiCTR2600121542)
    P=N/A, N=27, Shanxi Bethune Hospital; Shanxi Bethune Hospital
    New trial
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    EGFR mutation • ALK mutation
    |
    Keytruda (pembrolizumab)
    2d
    A prospective, single-arm clinical study of QL1706 monotherapy in elderly patients with driver gene-negative, PD-L1-positive NSCLC (ChiCTR2600121140)
    P=N/A, N=40, The Fourth Hospital of Hebei Medical University; The Fourth Hospital of Hebei Medical University
    New trial
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    PD-L1 expression • BRAF V600E • EGFR mutation • BRAF V600 • ALK mutation
    |
    PD-L1 IHC 22C3 pharmDx
    |
    Qibeian (iparomlimab/tuvonralimab)
    2d
    HS-20093-309: A Multicenter, Randomized, Open-Label, Controlled Phase III Clinical Study Evaluating the Efficacy and Safety of HS-20093 Injection Combined with Adebrelimab versus Docetaxel in Previously Treated Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer without Actionable Genomic Alterations (ChiCTR2600121048)
    P3, N=450, Shanghai Pulmonary Hospital; Shanghai Pulmonary Hospital
    New P3 trial
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • CD276 (CD276 Molecule)
    |
    PD-L1 expression • EGFR mutation • ALK fusion • ALK mutation • ROS1 fusion
    |
    docetaxel • AiRuiLi (adebrelimab) • risvutatug rezetecan (GSK5764227)
    2d
    Deep Learning-Based Multicenter Study on Intelligent Diagnosis and Treatment Response Assessment of Solid Tumors (ChiCTR2600120951)
    P=N/A, N=500, Recruiting, Wuxi people’s Hospital; Wuxi people’s Hospital
    New trial
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
    |
    PD-L1 expression • EGFR mutation • ALK mutation
    2d
    A prospective, randomized, double-arm, multi-center, phase II study to Investigate the Efficacy and Safety of Sintilimab in Combination with IpilimumabN01 and Chemotherapy in First-line Treatment of driver gene-negative advanced NSCLC with PDL1 TPS<1% (ChiCTR2600119741)
    P2, N=80, PLA General Hospital; PLA General Hospital
    New P2 trial
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    EGFR mutation • HER-2 mutation • ALK mutation • ROS1 fusion • MET mutation
    |
    PD-L1 IHC 22C3 pharmDx
    |
    Yervoy (ipilimumab) • Tyvyt (sintilimab) • pemetrexed
    2d
    A Phase 2, randomized, open-label, active-controlled study of JNJ-90301900 in combination with chemoradiation followed by durvalumab in locally advanced and unresectable Stage III non-small cell lung cancer (ChiCTR2600118958)
    P2, N=130, Shandong First Medical University Affiliated Tumor Hospital; Shandong First Medical University and Shandong Academy of Medical Sciences (Shandong Canc
    New P2 trial
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
    |
    EGFR mutation • ALK mutation
    |
    Imfinzi (durvalumab) • Hensify (crystalline hafnium oxide)
    2d
    Construction of an Artificial Intelligence System for Predicting the Efficacy of Lung Cancer Immunotherapy and Early Warning of Immune-Related Adverse Reactions Based on Multi-Modal Data (ChiCTR2600118816)
    P=N/A, N=5000, The First Affiliated Hospital of Wenzhou Medical University; The First Affiliated Hospital of Wenzhou Medical University
    New trial
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    EGFR mutation • ALK mutation
    2d
    A Prospective, Multicenter Study of Perioperative MRD-Guided Adjuvant Immunotherapy in Patients With Stage II–III Non-Small Cell Lung Cancer (ChiCTR2600118144)
    P2, N=120, Recruiting, Guangdong Provincial People's Hospital; Guangdong Provincial People's Hospital
    New P2 trial
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    EGFR mutation • ALK positive • ALK mutation
    |
    carboplatin • paclitaxel • pemetrexed • AiRuiLi (adebrelimab)
    4d
    Long-term outcomes and clinical features of stage III non-small-cell lung cancer harboring ALK rearrangements: a multicenter retrospective study of 176 patients. (PubMed, J Natl Cancer Cent)
    Stage III ALK-positive NSCLC is prone to relapse but local therapy combined with adjuvant ALK TKIs offers a promising strategy. Patients with EML4-ALK v1 mutations may show improved outcomes.
    Retrospective data • Journal
    |
    ALK (Anaplastic lymphoma kinase) • EML4 (EMAP Like 4)
    |
    ALK positive • ALK rearrangement • ALK mutation • RET rearrangement
    4d
    Lung Cancer Driver Mutations in Middle Eastern Americans: Associations with Smoking and Comparative Analysis with Middle Eastern Populations. (PubMed, Avicenna J Med)
    Understanding these dynamics is essential for developing targeted public health strategies that address the unique challenges faced by this population, balancing their cultural heritage with the realities of modern American life. Further analysis and wider scope studies are necessary to explore the implications of these findings on health outcomes.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    KRAS mutation • EGFR mutation • BRAF mutation • ALK positive • ALK mutation • MET mutation
    |
    TruSight Oncology 500 Assay • TruSight Tumor 15 Assay
    4d
    EGFR and ALK Targeted Therapy Response in Non-Small Cell Lung Cancer Harboring Rare or Resistant Mutations: A Case Report and Molecular Insights. (PubMed, Curr Cancer Drug Targets)
    The association between the docking predictions and clinical outcomes corroborates the utility of computational modeling for tailoring therapies, although the structural models provide mechanistic insight into drug efficacy against these rare mutations. The present integrated approach emphasizes the value of merging in silico methods into clinical decision-making to overcome the therapeutic uncertainty of uncommon oncogenic driver alterations.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    EGFR mutation • ALK mutation
    |
    Gilotrif (afatinib) • Alecensa (alectinib)
    5d
    UC-IMM-2511/2512: METAREM / META-1 - METAREM :Immunotherapy Master Trial for Advanced Cancers / META-1: Immunotherapy without chemotherapy for advanced lung cancer patients with high PD-L1 Levels. (2025-522655-26-00)
    P1/2, N=55, Not yet recruiting, Unicancer
    New P1/2 trial
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    ALK mutation
    |
    Keytruda (pembrolizumab) • Libtayo (cemiplimab-rwlc)